

Supplementary material E: Characteristics of included studies

Study	Year	Type	Baseline comparability	Group	disease duration(year)		Age(year)		Intervention		HCQ dose (mg/day)	Outcomes	Concurrent medications
					HG	CG	HG	CG	HG	CG			
Abd et al.[32]	2020	Cohort	YES	HG(47) NG(35)	7.06±4.24	6.57±3.56	32.03±3.92	31.50±3.54	HCQ	NS	NS	1234	COR,AZA, CsA
Canti et al.[14]	2021	Cohort	YES	HG(45) NG(29)	9±1	7±6	32.71±4.36	32.03±4.37	HCQ	NS	300	1234	ASA,LMW- H,AZA,COR
Clowse et al.[33]	2006	Cohort	YES	HG(56) NG(163)		NS			HCQ	NS	NS	123	PDN,AZA
Do et al.[34]	2020	Cohort	YES	HG(53) NG(76)	9.2±5.3	7.2±6.8	33.0±5.5	32.1±6.0	HCQ	NS	NS	1234	ASA,PDN, AZA,Antico- agulant
Kroese et al.[35]	2017	Cohort	NS	HG(30) NG(80)	4.5(3,10.8)	6(3.5,9.5)	32.5±4.3	30.6±4.0	HCQ	NS	200/400	234	NS
Leroux	2015	Cohort	YES	HG(41)		NS	31.2±5.7	30.0±5.4	HCQ	NS	400	1234	PDN,ASA,

et al.[16]				NG(77)										LMWH, AZA,IVIG
Seo et al.[36]	2019	Cohort	YES	HG(80) NG(71)		NS	32.8±4.2	31.8±3.6	HCQ	NS	NS	1234		AZA,COR,A -SA,LMWH
Cao ZJ et al.[37]	2012	Cohort	NS	HG(11) NG(12)	5.6(0.25-12)	5.6(0.25-12)	28.4(22-35)	28.4(22-35)	HCQ+ PDN	PDN	200	123		PDN
Chen GL.[38]	2021	Case- control	YES	HG(137) NG(40)		NS	29.6±4.2	29.9±4.3	HCQ	NS	NS	234		ASA,LMW- H,COR, Immunosupp -ressants
Deng RR.[39]	2017	Case- control	NS	HG(17) NG(67)	4.89±3.82	4.89±3.82	29.89±4.27	29.89±4.27	HCQ	NS	NS	2		COR,ASA, LMWH
Diao MX.[40]	2016	Cohort	YES	HG(34) NG(34)	4.8±2.6	4.8±2.6	25.8±3.3	25.8±3.3	HCQ+ PDN	PDN	400	2		PDN
Wu FQ et al.[41]	2019	Cohort	YES	HG(41) NG(41)	3.2±1.2	3.3±1.4	27.6±5.3	28.6±4.2	HCQ+ PDN	PDN	400	12		PDN, Immunosupp

													-ressants
Lin QR et al.[42]	2021	Cohort	YES	HG(34) NG(34)	3.50±1.09	3.65±1.11	29.45±6.50	28.35±6.42	HCQ+ PDN	PDN	400	12	PDN
Liu XY et al.[43]	2015	Cohort	YES	HG(30) NG(30)	5.4(2-12)	5.4(2-12)	27.5(22-35)	27.5(22-35)	HCQ+ PDN	PDN	200-400	12	PDN
Liu YQ et al.[44]	2013	Cohort	YES	HG(20) NG(20)	2-10	2-10	20-33	20-33	HCQ+ PDN	PDN	200-400	123	PDN
Zheng CS et al.[45]	2015	Cohort	YES	HG(26) NG(26)	3.7±1.4	4.9±1.8	28.4±7.3	26.3±6.1	HCQ+ PDN	PDN	200-400	123	PDN
Wang LH et al.[46]	2018	Cohort	YES	HG(35) NG(35)	5.7±4.3	5.6±4.1	28.5±7.3	28.4±7.1	HCQ+ PDN	PDN	200-400	123	PDN
Wang WJ et al.[47]	2018	Cohort	YES	HG(46) NG(46)	5.4±0.8	5.4±0.7	29.2±4.2	29.7±4.4	HCQ+ PDN	PDN	400	123	PDN

Wu MY.[48]	2014	Case-control	YES	HG(43) NG(40)	5.73±3.23	6.35±4.23	27.60±4.40	27.75±3.89	HCQ+ PDN	PDN	NS	1234	AZA,CsA, PDN
Zhang HQ.[49]	2019	Cohort	YES	HG(32) NG(32)		NS	29.6±2.8	28.4±2.5	HCQ+ PDN	PDN	400	23	Immunosupp -ressants
Zhou L et al.[50]	2017	Case-control	NS	HG(71) NG(43)	5.2±2.8	5.2±2.8	28±4	28±4	HCQ+ PDN	PDN	200	12	PDN

NS Not stated; **HG** HCQ group; **NG** non-HCQ group; **PDN** Prednisone; **1** SLE activity: flare, SLEDAI; **2** Pregnancy outcome: full-term birth, preterm birth, miscarriage, stillbirth; **3** Fetal outcome: fetal distress, IUGR, low birth weight, SGA; **4** Complications of pregnancy: Gestational hypertension, Pre-eclampsia, Gestational diabetes mellitus; **COR** Corticosteroids; **AZA** Azathioprine; **CsA** Cyclosporine A; **ASA** Aspirin; **LMWH** Low molecular weight heparin; **IVIG** Intravenous immunoglobulin.